Alpha-2 adrenergic agonists work by dampening sympathetic outflow, mainly through activation of alpha-2 receptors in the central nervous system, which lowers peripheral vascular resistance and blood pressure. Clonidine fits this mechanism, as it activates CNS alpha-2 receptors to reduce sympathetic tone, producing antihypertensive effects (and also used in other settings like withdrawal management). The other drugs here act on beta receptors instead: isoproterenol is a nonselective beta agonist that increases heart rate and bronchodilation; albuterol and salmeterol are beta-2 agonists used for bronchodilation. Since they do not activate alpha-2 receptors, they are not alpha-2 adrenergic agonists.

Aminoglycosides are most effective against aerobic Gram-negative bacteria. Their uptake into bacterial cells requires oxygen, so they are less active against anaerobes and most Gram-positive organisms. They work by binding to the 30S ribosomal subunit to disrupt protein synthesis, producing a bactericidal effect that is particularly strong against Gram-negative rods (like Enterobacterales and Pseudomonas). They have limited activity on fungi and viruses, and any significant Gram-positive activity is usually only in synergy with a cell-wall–active agent, not as standalone coverage. Therefore, their general strength lies in Gram-negative coverage.

The key idea is that a persistent cough is the side effect most commonly tied to ACE inhibitors. ACE inhibitors can raise levels of bradykinin in the airways, which can irritate the cough reflex and produce a dry, lingering cough in many patients. Angiotensin receptor blockers (ARBs) work differently: they block the angiotensin II receptor rather than inhibiting the enzyme that breaks down bradykinin, so bradykinin levels aren’t increased. That’s why ARBs are often chosen when a patient cannot tolerate the cough associated with ACE inhibitors. Dizziness, headache, and fatigue are possible with many blood pressure medications and aren’t specific clues for why a patient would switch from an ACE inhibitor to an ARB, so they don’t explain the choice as clearly.

The key idea is that fluoroquinolones kill bacteria by blocking two essential enzymes that manage DNA topology during replication: DNA gyrase and topoisomerase IV. DNA gyrase helps twist and unkink DNA by introducing negative supercoils, which is needed as the chromosome is copied. Topoisomerase IV is important for separating the newly replicated chromosomes so the daughter cells can be divided. When fluoroquinolones bind to these enzyme–DNA complexes, they prevent the enzymes from re-ligating the DNA strands, leading to stalled replication and lethal double‑strand DNA breaks. This action makes them bactericidal and explains why the statement about inhibiting DNA gyrase and topoisomerase IV is true. This mechanism is distinct from agents that disrupt cell wall synthesis, inhibit RNA polymerase, or block folate synthesis, which affect different bacterial processes.